Business
Neurocrine Biosciences develops and markets treatments for neurological, neuroendocrine and psychiatric disorders.
Neurocrine Biosciences converted strong product adoption into 21% growth, a 22% margin and nearly $750 million of free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 21.4%OK
- Profitability — Net income grew 40.2% to $478.6M from $341.3MOK
- Cash flow — Free cash flow grew 34.4% to $748.7M from $557.2MOK
- Margins — Operating margin contracted 258 bps to 21.64%Watch
- Accounting — Exceptional neuroscience product growthNote
- Insiders — 0 purchases and 20 salesWatch
Where the revenue comes from
Fiscal 2025, as NEUROCRINE BIOSCIENCES INC reports it. History and quarterly detail are in the app.
- Net product sales$2.8B
- Collaboration revenues$26.6M
Leadership changes
From NEUROCRINE BIOSCIENCES INC's own filings, the day they're filed.
- Eiry W. Roberts · Chief Medical Officer · appointmenteff. 2025-06-02
- Neurocrine Biosciences · Chief Medical Officer · appointmenteff. 2025-06-02
- Sanjay Keswani · Chief Medical Officer · appointmenteff. 2025-06-02
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about NEUROCRINE BIOSCIENCES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.